Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-05-24
2011-05-24
Wilson, James O (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S310700
Reexamination Certificate
active
07947723
ABSTRACT:
This invention provides for compounds, compositions, and methods that involve anti-proliferative and anti-neoplastic activity in cancer cells. In particular, a series of benzimidazole, purine, imidazopyridine, and imidazopyrizine compounds having selected substitution patterns are disclosed, and the activity of various subject compounds is demonstrated. For example, the invention provides compounds having the general formula:their pharmaceutical compositions, and methods of treatment using the subject compounds and compositions.
REFERENCES:
patent: 5314880 (1994-05-01), Whittaker et al.
patent: 5616601 (1997-04-01), Khanna et al.
patent: 5723485 (1998-03-01), Gungor et al.
patent: 6469040 (2002-10-01), Seibert et al.
patent: 6613789 (2003-09-01), Khanna et al.
patent: 7220770 (2007-05-01), Khanna et al.
patent: 2003/0036557 (2003-02-01), Khanna et al.
patent: 2003/0134853 (2003-07-01), Priestley et al.
patent: 2004/0067976 (2004-04-01), Priestley et al.
patent: 2005/0096368 (2005-05-01), Khanna et al.
patent: 2005/0256120 (2005-11-01), Khanna et al.
patent: 2006/0135553 (2006-06-01), Campbell et al.
patent: 2008/0249135 (2008-10-01), Slade et al.
patent: 2009/0099179 (2009-04-01), Klein et al.
patent: 1506355 (2004-06-01), None
patent: 663182 (1964-04-01), None
patent: 11060570 (1999-03-01), None
patent: WO 90/09997 (1990-09-01), None
patent: WO 9603388 (1996-02-01), None
patent: WO 9805639 (1998-02-01), None
patent: WO 03026587 (2003-04-01), None
patent: WO 2006050162 (2006-05-01), None
patent: WO 2006125539 (2006-11-01), None
patent: WO 2006125540 (2006-11-01), None
patent: WO 2007115306 (2007-10-01), None
Abdel-Monem, Wafaa R., “Synthesis and biological evaluations of sulfa derivatives bearing heterocyclic moieties,” Department of Chemistry, Faculty of Education, Ain-Shams University, Cairo, Egypt. Bollettino Chimico Farmaceutico (2004), 143(6), 239-247. Publisher: Societa Editoriale Farmaceutica, CODEN: BCFAAI ISSN: 0006-6648. CAN 144:331292 AN 2005:534819 (Abstract).
Almansa, Carmen, et al., “Synthesis and SAR of a New Series of COX-2 Selective Inhibitors: Pyrazolo[1,5-a]pyrimidines,”Journal of Medicinal Chemistry, 2001, vol. 44, No. 3, pp. 350-361.
Alvarez, F. J., et al., “3-phosphoinositide-dependent protein kinase-1/Akt signalling and inhibition in a canine prostate carcinoma cell line,” Department of Veterinary Clinical Sciences, College of Veterinary Medicine, The Ohio State University, Columbus, OH, USA. Veterinary and Comparative Oncology (2007), 5(1), 47-58.
Alvarez, F. J., et al., “3-phosphoinositide-dependent protein kinase-1/Akt signalling and inhibition in a canine prostate carcinoma cell line,” Department of Veterinary Clinical Sciences, College of Veterinary Medicine, The Ohio State University, Columbus, OH, USA. Veterinary and Comparative Oncology (2007), 5(2), 131 (Erratum).
American Cancer Society. “Cancer Facts & Figures 2009,” Atlanta: American Cancer Society; 2009.
Bassignana, P., et al., “Infrared absorption spectra of certain imidazole and selenazole derivatives. Investigation of the C.dbd.N bonds,” Spectrochimica Acta (1965), 21(3), 605-13. CODEN: SPACA5 ISSN: 0038-6987. CAN 62:48135 AN 1965:48135 (Abstract).
Bystrov, V.F., et al., “Reactivity constants of some 2-hetaryls,” Inst. Org. Khim., Kiev, USSR. Zhurnal Obshchei Khimii (1968), 38(5), 1001-5. CODEN: ZOKHA4 ISSN: 0044-460X. Journal written in Russian. CAN 69:96568 AN 1968:496568 (Abtract).
Caron, Ruben W., et al., “Activated forms of H-RAS and K-RAS differentially regulate membrane association of PI3K, PDK-1, and AKT and the effect of therapeutic kinase inhibitors on cell survival,” Departments of Radiation Oncology and Hematology/Oncology, Virginia Commonwealth University, Richmond, VA, USA. Molecular Cancer Therapeutics (2005), 4(2), 257-270.
Cen, L., et al., “PDK-1/AKT pathway as a novel therapeutic target in rhabdomyosarcoma cells using OSU-03012 compound,” Center for Childhood Cancer, Columbus Children's Research Institute, Department of Pediatrics, Ohio State University, Columbus, OH, USA. British Journal of Cancer (2007), 97(6), 785-791.
Crowder, Robert J., et al., “Treating breast cancer through novel inhibitors of the phosphatidylinositol 3′-kinase pathway,” Department of Medicine, Division of Oncology, Washington University School of Medicine and Siteman Cancer Center, St. Louis, MO, USA. Breast Cancer Research (2005), 7(5), 212-214.
Cui, Wei, et al., “In-vivo effects and mechanisms of celecoxib-reduced growth of cyclooxygenase-2 (COX-2)-expressing versus COX-2-deleted human HCC xenografts in nude mice,”Anti-Cancer Drugs2008, vol. 19, No. 9, pp. 891-897.
Dent, Paul, et al., “DMC: novel celecoxib derivatives to rap cancer,” Department of Biochemistry, Massey Cancer Center, Virginia Commonwealth University, Richmond, VA, USA. Cancer Biology & Therapy (2005), 4(5), 583-584.
Devarenne, Timothy P., et al., “Adi3 is a Pdk1-interacting AGC kinase that negatively regulates plant cell death,” Boyce Thompson Institute for Plant Research, Ithaca, NY, USA. EMBO Journal (2006), 25(1), 255-265.
Evans, D., et al., “Synthesis of a group of 1H-benzimidazoles and their screening for antiinflammatory activity,”Eur J Med Chem(1996) 31, 635-642.
Fichert, Thomas, “A Structure-Permeability Study of Small Drug-like Molecules,”Bioorganic&Medicinal Chemistry letters13 (2003) 719-722.
Franke, Lutz, et al., “Extraction and Visualization of Potential Pharmacophore Points Using Support Vector Machines: Application to Ligand-Based Virtual Screening for COX-2 Inhibitors,”Journal of Medicinal Chemistry, 2005, vol. 48, No. 22, pp. 6997-7004.
Gao, Ming, et al., “OSU-03012, a Novel Celecoxib Derivative, Induces Reactive Oxygen Species-Related Autophagy in Hepatocellular Carcinoma,”Cancer Res2008; 68:(22), Nov. 15, 2008, pp. 9348-9357.
Gieselman, Melinda B., et al., “Water-soluble polybenzimidazole-based polyelectrolytes,”Macromolecules, 1992, 25 (18), 4832-4834.
Haiming, Ding, et al., “OSU03012 activates Erk1/2 and Cdks leading to the accumulation of cells in the S-phase and apoptosis,” Department of Radiology, College of Medicine, The Ohio State University, Columbus, OH 43210, USA. International journal of cancer. Journal international du cancer (2008), 123(12), 2923-30.
Haiming, Ding, et al., “Sensitivity to the non-COX inhibiting celecoxib derivative, OSU03012, is p21(WAF1/CIP1) dependent,” Department of Radiology, College of Medicine, The Ohio State University, Columbus, OH 43210, USA. International journal of cancer. Journal international du cancer (2008), 123(12), 2931-8.
Jerchel, Dietrich, et al., “Preparation of benzimidazoles,” Johannes Gutenberg Univ., Mainz, Germany. Annalen der Chemie, Justus Liebigs (1952), 575 162-73. CODEN: 9X224Y CAN 47:15855 AN 1953:15855 (Abstract).
Johnson, Amy J., et al., “A novel celecoxib derivative, OSU03012, induces cytotoxicity in primary CLL cells and transformed B-cell lymphoma cell line via a caspase- and Bcl-2-independent mechanism,” Division of Hematology and Oncology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA. Blood (2005), 105(6), 2504-2509.
Junan, Li, et al., “A structurally optimized celecoxib derivative inhibits human pancreatic cancer cell growth,” Departments of Surgery and Internal Medicine, College of Medicine, The Ohio State University, 410 West 10th Avenue, Columbus, OH 43210, USA Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract (2006), 10(2), 207-14.
Kardosh, Adel, et al., “Dimethyl-Celecoxib (DMC), a Derivative of Celecoxib that Lacks Cyclooxygenase-2-Inhibitory Function, Potently Mimics the Anti-Tumor Effects of Celecoxib on Burkitt's Lymphoma In Vitro and In Vivo,” Cancer Biology & Therapy (2005), 4(5), 571-58
Spelman College
Sutherland & Asbill & Brennan LLP
Willis Douglas M
Wilson James O
LandOfFree
Synthesis and anti-proliferative effect of benzimidazole... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Synthesis and anti-proliferative effect of benzimidazole..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Synthesis and anti-proliferative effect of benzimidazole... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2650994